AstraZeneca reports positive COPD data for Bevespi Aerosphere

AstraZeneca has announced new clinical trial data that demonstrates the benefits offered by the chronic obstructive pulmonary disease (COPD) therapy Bevespi Aerosphere.

Positive top-line results have been reported from the phase III PINNACLE 4 trial, in which Bevespi Aerosphere was shown to be associated with better lung function performance among patients with moderate to very severe COPD.

Statistically significant lung function improvements, as measured by trough forced expiratory volume in one second, were achieved when patients were treated with Bevespi Aerosphere rather than its monotherapy components, glycopyrronium and formoterol fumarate.

A total of 1,756 patients across Asia, Europe and the US were involved in this study, which also produced positive safety and tolerability results.

Dr Colin Reisner, head of respiratory medicines development at AstraZeneca, said: "PINNACLE 4 will support our regulatory filings in Japan and China where respiratory diseases such as COPD remain a significant and growing public health burden with unmet treatment needs."

Bevespi Aerosphere is approved in the US for the long-term maintenance treatment of airflow obstruction in COPD. It has also been accepted for review by the European Medicines Agency, with a regulatory decision expected later this year.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.